PSI Names Andrea Cracraft Director Clinical Operations North America

PSI Names Andrea Cracraft Director Clinical Operations North America

ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, a full-service contract research organization, announced today the appointment of Andrea Cracraft as Director, Clinical Operations North America.

Ms. Cracraft has more than 15 years of experience in clinical research and joins PSI after spending 8 years in various senior roles with another global CRO. She brings a depth of pharmaceutical expertise in running global projects in various therapeutic areas, including Oncology, Respiratory, CNS, Musculoskeletal, Cardiovascular, and Genitourinary.

Ms. Cracraft stated, "This is a remarkable opportunity and I am delighted to have joined PSI. PSI is known for keeping and developing talent. I am happy to have a chance to contribute to the growth of clinical operations in North America and to build upon the company's excellent reputation for delivering clinical trials on-schedule and on-budget for our clients."

About PSI CRO: PSI is a privately-held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of their commitment to be the best CRO in the world as measured by their clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.